uniQure sales and marketing update

Germany’s Federal Joint Committee (G-BA) issued a final benefit assessment stating that the additional benefit was not quantifiable from gene therapy Glybera alipogene tiparvovec from uniQure to treat lipoprotein lipase (LPL) deficiency. uniQure said the decision was in line with the benefit assessment that uniQure had requested and will allow the company to proceed with pricing negotiations in Germany, which are expected to last three to six months. uniQure believes the decision will not negatively affect pricing negotiations. G-BA had postponed its assessment of Glybera earlier this month (see BioCentury, April 27). ...